Home › Bladder Cancer › New Jersey › Clifton
Bladder Cancer clinical trials in Clifton, NJ
3 studies for Bladder Cancer are looking for participants at sites in and around Clifton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
RecruitingPhase 3
- Hackensack University Medical Center, Hackensack · 7 mi away
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
RecruitingPhase 2
- Hackensack University Medical Center, Hackensack · 7 mi away
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecruitingPhase 1
- Hackensack University Medical Center, Hackensack · 7 mi away
About Bladder Cancer
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
More about Bladder Cancer on MedlinePlus
Bladder Cancer trials in other cities
- New York City, NY35 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Dallas, TX27 studies
- Boston, MA26 studies
- Washington, DC26 studies
- Los Angeles, CA24 studies
- Baltimore, MD24 studies
- St. Louis, MO22 studies
- Philadelphia, PA21 studies
- Seattle, WA21 studies
- Edison, NJ21 studies
Other studies in Clifton
- Non-Small Cell Lung Cancer24 studies
- Cancer (all types)15 studies
- Multiple Myeloma14 studies
- Metastatic Cancer12 studies
- Acute Myeloid Leukemia12 studies
- Prostate Cancer12 studies
- Breast Cancer12 studies
- Ovarian Cancer11 studies
- Lung Cancer10 studies
- Endometrial Cancer8 studies
- Triple-Negative Breast Cancer8 studies
- Colorectal Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.